Publications in the public press with GBCA authors 

By Erin Price Schabert and Kiersten Gallagher, Smith Center for Healing and the Arts
Mar 1, 2017  

“You won’t understand the unabashed power of a community until you are in one.” – Author Jon Acuff

There is power in community — a strength that comes with standing together with others in unity — a shared sense of purpose and vision. Many groups come together naturally: families, neighborhoods, schools, or sports teams. Other times finding your community — your people — can be a bit harder.

by Carole O’Toole, MS, and Erin Price Schabert, 2017

A common experience for people living with cancer – whether they are newly diagnosed, in treatment, dealing with a recurrence, or in survivorship – is the feeling of being overwhelmed by all the information given them and the multiple, often dif­ficult decisions they must make. The healthcare system can be daunting when any of us is dealing with a routine health issue. But with cancer, it can feel near­ly impossible to manage it all.

Fortunately, there are professionals whose job it is to help guide survivors and caregivers through the cancer maze. These individuals are called patient navigators.

November 11, 2015

A little insight into what kids see when you don't know they're looking, and how I came in second place to Thomas Edison.

When I was diagnosed with cancer, my kids were five and eight years old. Instantly at diagnosis, I thought of them. Somehow, I wasn’t worried that I would die, or even that it would be hard for me to manage the side effects of treatment.

October 31, 2015

An academically trained skeptic, this single project has turned me into a raving optimist.

Imagine you are a big drug company, testing out a new drug. You pick a group of people who you think are most likely to respond to the drug. If you give the new drug to ten cancer patients and nine of them have progressive disease — their tumors continue to grow — then you’re probably going to shelve that drug. You wouldn’t possibly want to give a drug to a group of patients when 90 percent of them will continue to get worse. But what about that one patient?